Jump to Main Content
Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates
- Zhang, Xuefeng, Wang, Jing, Lu, Jing, Li, Rongrong, Zhao, Shuli
- Virology journal 2018 v.15 no.1 pp. 137
- Hepatitis B virus, Primates, immunogenicity, safety assessment, vaccines
- Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China.